Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.
The data show an unexpected high rate and pattern of tumor recurrence coinciding with HCV clearance and, although based in a very small cohort of patients, should be taken as a note of caution and prime a large scale assessment that exceeds the individual investigators capacity.
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
The current treatment rate and efficacy are not sufficient to manage the disease burden of hepatitis C virus and alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver‐related deaths from increasing.
Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement
The subset of ascitic cirrhotic patients with marked immune and hemodynamic derangement is identified by increased LBP levels, which suggests the involvement of enteric bacteria or their products in the triggering of the process.
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
An open-label study assessing the safety and efficacy of ledipasvir, sofosbuvir, and ribavirin in patients with HCV genotype 1 or 4 and advanced liver disease found high rates of sustained virological response 12 weeks after treatment.
Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution
Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution is noted.
Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation.
- J. Turnés, J. García‐Pagán, +10 authors J. Bosch
- MedicineClinical gastroenterology and hepatology : the…
- 1 December 2008
Most patients not achieving recanalization will develop gastroesophageal varices during follow-up, however, development of variceal bleeding and ascites is infrequent, and survival is satisfactory.
Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis.
In a randomized controlled trial, addition of simvastatin to standard therapy did not reduce rebleeding, but was associated with a survival benefit for patients with Child-Pugh class A or B cirrhosis.
Historical epidemiology of hepatitis C virus (HCV) in selected countries
In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use, and Diagnosis, treatment and transplant levels also differed considerably between countries.
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
BACKGROUND & AIMS Risk scores for hepatocellular carcinoma (HCC) developed in Asians offer poor-moderate predictability in Caucasian patients with chronic hepatitis B (CHB). This nine center cohort…
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa‐2a plus ribavirin
Although the study failed to show a statistically significant difference between arms, it did show an improved SVR in females, and adding metformin to peginterferon and ribavirin was safe and improved insulin sensitivity.